SCHEMBL6350962

SCHEMBL6350962

CC(Nc1cccc(-c2ccccc2)c1CN)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
ATP1A1 P05023 4/20 0.40
ATP1B1 P05026 4/20 0.40
ATP1A3 P13637 4/20 0.40
ATP1B2 P14415 4/20 0.40
ATP1A2 P50993 4/20 0.40
ATP1B3 P54709 4/20 0.40
FXYD2 P54710 4/20 0.40
ATP1A4 Q13733 4/20 0.40
TAAR1 Q96RJ0 2/20 0.40
LDHA P00338 1/20 0.39
LDHB P07195 1/20 0.39
MAPT P10636 4/20 0.39
HTT P42858 2/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6344376 0.86 DPP4 (0.42) ADRA2AADRA2BADRA2CMAOAMAOB
SCHEMBL6350072 0.73 ALDH1A1 (0.43) ADRA2AADRA2BADRA2CMAOAMAOB
SCHEMBL6346667 0.73 TDP1 (0.46) TAAR1MAPTHTTLMNAMAPK1
SCHEMBL18027646 0.73 MEN1 (0.53) ADRA2ATAAR1HTTLMNAMEN1
SCHEMBL27670029 0.73 DPP4 (0.60) TAAR1MAPK1RAB9APDCD1CD274
SCHEMBL6344385 0.73 DPP4 (0.43) MAPTHTTLMNAMAPK1MEN1
Hydrogen Sulfide SCHEMBL27639876 0.71 DPP4 (0.58) TAAR1MAPK1RAB9APDCD1CD274
SCHEMBL6344769 0.71 HSD17B10 (0.46) ADRA2AADRA2BADRA2CMAOAMAOB
SCHEMBL6366941 0.69 MAPT (0.57) MAOAMAPTHTTLMNAMAPK1
SCHEMBL6350964 0.69 L3MBTL1 (0.42) ADRA2AMAOAMAOBTAAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075352-A1 3,4-Dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075352-A1 3,4-Dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors MAPKAPK2, MAPKAPK3, CREBBP ADRA2A 1468/4885ADRA2B 745/4885ADRA2C 918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.